## ICMJE DISCLOSURE FORM

| Date:                         | 1/14/2023  |
|-------------------------------|--|
| Your Name:                    | Genevieve Gilson   |
| Manuscript Title:             | Opioid-Sparing Opportunities in the Thoracic Surgery Pathway |
| Manuscript Number (if known): | Click or tap here to enter text.                             |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |  |
|---|---|--|---|--|
|   |   | Time frame: Since the initial planning of the work   |   |  |
|   | All support for the<br>present<br>manuscript (e.g.,<br>funding, provision<br>of study materials,<br>medical writing,<br>article processing<br>charges, etc.)<br><b>No time limit for<br/>this item.</b> | [⊠] None<br>[  | Click the tab key to add additional rows.   |  |
|   | Time frame: past 36 months  |  |   |  |
| 2 | Grants or<br>contracts from<br>any entity (if not<br>indicated in item<br>#1 above).  | [⊠] None   |   |  |
| 3 | Royalties or<br>licenses  | ☑    None      □    □      □    □  |   |  |

|    |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|---|--|---|
| 4  | Consulting fees   | ☑    None      [   |   |
| 5  | Payment or<br>honoraria for<br>lectures,<br>presentations,<br>speakers<br>bureaus,<br>manuscript<br>writing or<br>educational<br>events | None   |   |
| 6  | Payment for<br>expert testimony   | [⊠] None<br>[  |   |
| 7  | Support for<br>attending<br>meetings and/or<br>travel   | [⊠] None<br>[  |   |
| 8  | Patents planned,<br>issued or<br>pending  | [⊠] None   |   |
| 9  | Participation on<br>a Data Safety<br>Monitoring<br>Board or<br>Advisory Board   | [⊠] None   |   |
| 10 | Leadership or<br>fiduciary role in<br>other board,<br>society,<br>committee or<br>advocacy group,<br>paid or unpaid                     | [⊠] None   |   |

|   |   | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|---|--|---|
| 11  | Stock or stock<br>options   | [⊠] None   |   |
| 12  | Receipt of<br>equipment,<br>materials, drugs,<br>medical writing,<br>gifts or other<br>services | [⊠] None   |   |
| 13  | Other financial or<br>non-financial<br>interests  | ⊠  None  |   |
| Please place an "X" next to the following statement to indicate your agreement: |   |  |   |

## ICMJE DISCLOSURE FORM

Date:\_\_\_\_\_January 14, 2023\_\_\_\_\_\_ Your Name:\_\_\_Sandeep J. Khandhar\_\_\_\_\_\_

Manuscript Title:\_\_\_ Opioid-Sparing Opportunities in the Thoracic Surgery Pathway\_\_\_

Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains

to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items,

the time frame for disclosure is the past 36 months.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |  |
|---|--|---|---|--|
|   | Time frame: Since the initial planning of the work   |   |   |  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> | XNone   |   |  |

|   |  | Time frame: past  | 36 months |
|---|--|---|-----------|
| 2 | Grants or contracts from any<br>entity (if not indicated in<br>item #1 above).   | _XNone  |           |
|   |  |   |           |
|   |  |   |           |
| 3 | Royalties or licenses  | XNone   |           |
|   |  |   |           |
|   |  |   |           |
| 4 | Consulting fees  | Consultant, Advisory Board<br>member, International PI<br>for Medtronic. 2016-<br>present |           |
|   |  |   |           |
|   |  |   |           |
| 5 | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events | Bristol Myers Squibb 2019-<br>2023  |           |
|   |  | Astra Zeneca  |           |
|   |  | Medtronic   |           |
| 6 | Payment for expert<br>testimony  | Expert testimony for the defense 2022-2023  |           |
|   |  |   |           |
|   |  |   |           |
| 7 | Support for attending<br>meetings and/or travel  | Intuitive Surgical  |           |
|   |  |   |           |
| 8 | Patents planned, issued or pending   | XNone   |           |
|   |  |   |           |
|   |  |   |           |
|   |  |   |           |

| 9         | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board                   | Bristol Myers Squibb 2019-<br>2023 |   |
|-----------|---|------------------------------------|---|
|           |   | Astra Zeneca 2019-2023             |   |
|           |   |                                    |   |
| 10        | Leadership or fiduciary role  | _XNone                             |   |
|           | in other board, society,<br>committee or advocacy   |                                    |   |
| group, pa | group, paid or unpaid   |                                    |   |
| 11        | Stock or stock options  | Medtronic                          | Medtronic   |
|           |   |                                    |   |
|           |   |                                    |   |
| 12        | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services | Medical writing support            | Medtronic 2016-2022 International PI for clinical trial |
|           |   |                                    |   |
|           |   |                                    |   |
| 13        | Other financial or non-<br>financial interests  | XNone                              |   |
|           |   |                                    |   |
|           |   |                                    |   |

## Please summarize the above conflict of interest in the following box:

Over the past 3 years:

Consultant, advisory board member, speaker and PI for Medtronic. Travel support provided.

Advisory board member and speaker for Astra Zeneca.

Advisory board member and speaker for Bristol Myers Squibb. Travel support provided.

Intuitive surgical travel support provided.

None of these relationships are pertinent to the work submitted but included in the interest of full disclosure.

Please place an "X" next to the following statement to indicate your agreement:

\_X\_\_ I certify that I have answered every question and have not altered the wording of any of the questions on this

form.